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of prospective trials in these high-risk patients. Prelimi-An International Symposium entitled “Lipids and Re-
nary studies with various approaches to lipid-loweringnal Disease” was held in Kashikojima, Japan, on October
therapies, both pharmacological and apheresis, also un-8–11, 1998. The meeting provided an opportunity for
derscore the need for prospective clinical trials in pa-nearly 300 leading investigators and clinicians from Ja-
tients with progressive renal disease.pan, Europe, Australia, and the United States to meet
We trust that the readers of this issue of Kidney Inter-and discuss advances in lipid metabolism and their patho-
national will find new and insightful information per-physiological roles in vascular and renal injury in patients
taining to the role of lipids in renal disease. The Organiz-with kidney disease. Critical to the success of this meeting
ing and Scientific Committees along with the co-Guestwas the development of focused areas for future research
Editors would like to recognize the invaluable contribu-in the area of vascular injury and repair. In addition,
tions of all the participants to the success of this meeting.new insights into the mechanisms whereby lipids may
The timely publication of the proceedings attests to themodulate progressive renal injury were discussed. Of par-
commitment of all participants to the highest academicticular interest was the dramatic expansion of our under-
standards.standing of the mechanisms whereby lipid-lowering agents
We acknowledge the generous support of the variousmay influence biological processes involved in vascular
sponsors who provided unrestricted educational grants.and progressive renal injury. From a clinical perspective,
This included the Association of Japanese Pharmaceuti-new studies regarding the important relationship be-
cal Manufacturers, Baxter Healthcare Corporation, No-tween renal disease and cardiovascular disease were pre-
vartis Pharma KK, Sankyo Co., Ltd., Daiichi Pharmaceu-sented. The relationship between proteinuria and cardio-
tical Co., Ltd., Eisai Co., Ltd., and Tanabe Seiyaku Co.,vascular disease was striking and underscored the need
Ltd. The assistance of Ms. Deanna Gunderson was in-for new therapeutic trials with lipid-lowering treatments
valuable throughout all of the phases of meeting prepara-in this high-risk group of patients. The presentations on
tion and the publication of this supplement. Finally, Ms.the poor outcomes of acute myocardial infarctions in
Suenaga of JTB Communications, Inc., provided the nec-dialysis patients were just as notable. Underutilization
essary meeting logistics to allow for an excellent venue.of pharmacological therapies that have been shown to
influence cardiovascular outcomes in other patient popu- William F. Keane, Susumu Yukawa, and Masatoshi Mune
Guest Editorslations was of note and, again, begs for the development
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